Provigil and PPIs (Omeprazole, Pantoprazole): Interaction Explained
Modafinil (brand name Provigil) is an FDA-approved wakefulness-promoting agent used for narcolepsy, shift-work sleep disorder, and as an adjunct in obstructive sleep apnea. It is not a stimulant in the amphetamine sense, but it shares a relevant property with many other drugs: part of its metabolism runs through the liver enzyme CYP2C19, the same enzyme that proton pump inhibitors (PPIs) such as omeprazole (Prilosec) and pantoprazole (Protonix) both depend on and act upon.
The direct answer: modafinil and PPIs can be combined, and this combination is not flagged as contraindicated on the modafinil label, but it involves a two-way pharmacokinetic interaction through CYP2C19 that is plausible and mechanistically well-described, though not confirmed by a dedicated clinical trial in patients taking both drugs together. Omeprazole and esomeprazole are stronger CYP2C19 inhibitors than pantoprazole or rabeprazole, so the two directions of concern (modafinil levels rising, PPI effectiveness falling) are expected to be more pronounced with omeprazole-class PPIs than with pantoprazole.
The core mechanism: a shared enzyme, two opposite effects
CYP2C19 metabolizes both drug classes here, but the direction of effect differs depending on which drug you look at.
Omeprazole and esomeprazole are metabolized substantially by CYP2C19 and also inhibit that same enzyme. This is a well-established pharmacological property of the omeprazole class, described in foundational pharmacogenetics literature on CYP2C19 polymorphism. Pantoprazole and rabeprazole share the same metabolic pathway but are generally regarded as weaker CYP2C19 inhibitors, which is why they are sometimes preferred in patients on other CYP2C19-dependent drugs.
Modafinil affects CYP2C19 in the other direction. The FDA-approved prescribing information for Provigil describes modafinil as having effects on CYP2C19 and CYP3A4/5 metabolism, and it lists omeprazole among the drugs whose plasma concentrations may be altered as a result (FDA label, Provigil, revised 2015). The exact wording of the label's interaction language should be checked directly against the current label text before it is quoted verbatim in any patient-facing or prescribing material; treat any close paraphrase here as needing that verification, not as a confirmed direct quotation.
Putting the two together: omeprazole's CYP2C19 inhibition can plausibly raise modafinil exposure, while modafinil's effect on CYP2C19 can plausibly lower omeprazole exposure. Both directions are mechanistically coherent given what is known about the enzyme, but the magnitude of each effect in real patients taking both drugs has not been established by a dedicated pharmacokinetic study identified for this review.
Modafinil and PPIs interact through CYP2C19 in opposite directions: PPIs (most strongly omeprazole and esomeprazole) can inhibit modafinil's minor CYP2C19 clearance pathway, while modafinil can reduce CYP2C19-dependent PPI metabolism. This interaction is classified as moderate by most drug-interaction references, is not a reason to avoid the combination outright, and its real-world magnitude in co-treated patients has not been confirmed by a dedicated clinical trial as of this review (January 2025).
Does gastric pH change matter here?
PPIs raise gastric pH, which can reduce the absorption of drugs whose solubility depends on an acidic stomach environment (itraconazole and atazanavir are commonly cited examples). Modafinil is not considered pH-sensitive in this way based on its physicochemical properties, so the absorption route is not expected to be a meaningful part of this interaction. The CYP2C19 enzyme pathway, not gastric pH, is the mechanism that matters for modafinil and PPIs.
How this differs by PPI
Not all PPIs carry the same theoretical interaction risk, because they differ in how strongly they inhibit CYP2C19.
- Omeprazole and esomeprazole: regarded as stronger CYP2C19 inhibitors among PPIs; theoretically the highest-risk pairing with modafinil.
- Lansoprazole: an intermediate CYP2C19 inhibitor; theoretically a smaller effect than omeprazole.
- Pantoprazole and rabeprazole: generally regarded as the weakest CYP2C19 inhibitors of the class; theoretically the lowest-risk pairing with modafinil when acid suppression is needed alongside modafinil therapy.
This ranking reflects general pharmacology of the PPI class rather than a study specific to modafinil co-administration, and it should be treated as a reasonable basis for drug selection, not as a quantified risk difference.
CYP2C19 genetics change the picture
CYP2C19 has well-documented functional variants. A meaningful minority of people, more common in some Asian populations than in White or Black populations, are "poor metabolizers" who clear CYP2C19 substrates slowly. In poor metabolizers, baseline PPI exposure is already higher than in extensive metabolizers, so adding modafinil's effect on CYP2C19 into that background is harder to predict without genotype information. Ultra-rapid metabolizers, at the other end of the spectrum, may process both drugs quickly enough that neither the modafinil nor the PPI direction of this interaction becomes clinically apparent. Where genotype information is not available, this variability is a reason for symptom-based monitoring rather than assuming a fixed percentage change in either drug's exposure.
What is established, what is plausible, and what is not established
| Status | Statement | Basis |
|---|---|---|
| Established | Modafinil's FDA label identifies effects on CYP2C19-dependent metabolism and names omeprazole as an affected drug. | FDA-approved labeling (verify exact current wording against the label directly) |
| Established | Omeprazole and esomeprazole are stronger CYP2C19 inhibitors than pantoprazole and rabeprazole. | General PPI pharmacology, widely described in pharmacokinetic literature on this drug class |
| Established | CYP2C19 has common functional genetic variants that change drug clearance, with prevalence differing by ancestry. | Well-documented pharmacogenomic finding |
| Plausible, not confirmed by a dedicated trial | Omeprazole meaningfully raises modafinil plasma levels in typical clinical use. | Mechanistically consistent with CYP2C19 inhibition; no head-to-head trial identified |
| Plausible, not confirmed by a dedicated trial | Modafinil meaningfully lowers omeprazole plasma levels or reduces acid-suppression efficacy in typical clinical use. | Mechanistically consistent with CYP2C19 induction/inhibition effects described in the label; magnitude unconfirmed |
| Not established | A specific numeric AUC change (for example, a defined percentage increase or decrease) for either drug when co-administered. | No dedicated pharmacokinetic study of this specific pair was identified for this review |
| Not established | Whether modafinil clinically reduces H. pylori eradication success when combined with omeprazole-based triple therapy. | Extrapolated from general CYP2C19 pharmacology; not confirmed by a study of this specific combination |
| Requires clinician/pharmacist verification | Any specific dose-adjustment recommendation for an individual patient. | Depends on indication, dose, genotype (if known), and comorbidities; outside the scope of a general information page |
Practical monitoring approach
Because the confirmed magnitude of this interaction is not established, the most defensible approach is symptom-based monitoring rather than a fixed dose rule.
For the PPI side of the interaction: ask whether reflux, heartburn, or dyspepsia symptoms that were previously controlled have returned within a few weeks of starting or increasing modafinil. Breakthrough symptoms are a signal to review PPI choice and dose with the prescriber, not to independently increase the PPI dose.
For the modafinil side of the interaction: watch for new or worsening insomnia, headache, palpitations, tachycardia, or anxiety after starting or increasing an omeprazole-class PPI. These can indicate higher modafinil exposure, though they are not specific to this interaction and have other possible causes.
Timing does not fix this interaction. Because the mechanism is hepatic enzyme induction and inhibition rather than competition for absorption, spacing the two doses apart in the day does not meaningfully change the pharmacokinetic interaction.
PPI substitution is a reasonable option to discuss. If acid suppression is needed long-term alongside modafinil, pantoprazole or rabeprazole are pharmacologically lower-risk choices than omeprazole or esomeprazole, based on their weaker CYP2C19 inhibition, though this has not been tested specifically in modafinil-treated patients.
Genotype testing is an option, not a requirement. CYP2C19 genotyping is available through some clinical and direct-to-consumer pharmacogenomic panels. It is not required to use modafinil and a PPI together, but it can help explain an unusually strong or absent response in an individual patient.
Special situations worth flagging to a prescriber
- H. pylori eradication therapy. Standard triple therapy commonly includes a PPI. If modafinil reduces PPI exposure during this course, it is a theoretical concern for eradication efficacy, though this has not been directly studied. Discuss timing of modafinil around an eradication course with the prescribing clinician.
- Cardiac history. Modafinil's label carries cautions in patients with certain cardiac conditions. If a PPI is expected to raise modafinil exposure, a lower starting modafinil dose and closer monitoring for palpitations or tachycardia is a reasonable, individualized discussion with a prescriber rather than a fixed rule.
- Older adults. CYP2C19 activity can decline modestly with age, and older adults are more likely to be on both a PPI and modafinil or armodafinil for various indications. This is a reason for a more conservative starting approach and closer follow-up, decided by the prescribing clinician.
None of these scenarios should be managed by self-adjusting a PPI or modafinil dose. Contact the prescribing clinician or a pharmacist for individualized guidance, and seek urgent care for chest pain, significant palpitations, or signs of an allergic reaction.
Where the evidence gap actually is
The mechanism connecting modafinil and PPIs through CYP2C19 is well described at the level of enzyme pharmacology and is reflected in modafinil's FDA labeling. What is missing is a dedicated pharmacokinetic study enrolling patients on both drugs together that would allow a specific, quantified claim about how much modafinil or PPI exposure actually changes in practice. In the absence of that study, interaction databases and this article rely on mechanistic reasoning from CYP2C19 pharmacology, which is a reasonable basis for caution and monitoring but should not be mistaken for a confirmed, measured effect size.
Common questions
Can I take Provigil with a PPI like omeprazole or pantoprazole? Generally yes. It is not listed as a contraindicated combination, but it involves a CYP2C19-mediated interaction that is mechanistically plausible in both directions. Tell the prescriber about both medications so they can decide whether monitoring or a PPI change makes sense for the specific situation.
Which PPI carries the lowest theoretical interaction risk with modafinil? Pantoprazole and rabeprazole are weaker CYP2C19 inhibitors than omeprazole or esomeprazole, so they are the pharmacologically lower-risk choices when a PPI is needed alongside modafinil. This is based on general PPI pharmacology, not a study of this specific pairing.
Does spacing out the doses reduce the interaction? No. The interaction operates through liver enzyme effects, not competition for absorption, so timing separation does not meaningfully change the pharmacokinetic effect.
What symptoms suggest the interaction is happening in a specific patient? Returning reflux or heartburn symptoms suggest reduced PPI effectiveness; new insomnia, headache, palpitations, or anxiety suggest higher modafinil exposure. Either pattern is a reason to contact the prescriber rather than adjust doses independently.
Reference
U.S. Food and Drug Administration. Provigil (modafinil) Prescribing Information, Cephalon Inc., revised 2015: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020717s037s038lbl.pdf
Specific interaction magnitudes and exact labeling language are not provided here, as reported figures vary between sources and have not been independently confirmed. Clinicians should consult current prescribing information and primary literature for precise values.